ATE301657T1 - Azolo-pyrimidine - Google Patents

Azolo-pyrimidine

Info

Publication number: ATE301657T1
Authority: AT; Austria
Prior art keywords: azolo; pyrimidines; crf; psychiatric; immunological
Prior art date: 1998-01-28

Application number

AT03075887T

Other languages

English (en)

Inventor

Liqi He

Paul Gilligan

Robert Chorvat

Argyrios Georgios Arvanitis

Original Assignee

Bristol Myers Squibb Pharma Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-28

Filing date

1999-01-28

Publication date

2005-08-15

1998-01-28 Priority claimed from US09/014,734 external-priority patent/US6313124B1/en

1998-01-28 Priority claimed from US09/015,001 external-priority patent/US6060478A/en

1998-01-28 Priority claimed from US09/015,002 external-priority patent/US6191131B1/en

1999-01-28 Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co

2005-08-15 Application granted granted Critical

2005-08-15 Publication of ATE301657T1 publication Critical patent/ATE301657T1/de

Links

102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 2
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 2
239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 2
208000019901 Anxiety disease Diseases 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000000112 colonic effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
230000009610 hypersensitivity Effects 0.000 abstract 1
230000001900 immune effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Virology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Rheumatology (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)

AT03075887T 1998-01-28 1999-01-28 Azolo-pyrimidine ATE301657T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/014,734 US6313124B1 (en)	1997-07-23	1998-01-28	Tetrazine bicyclic compounds
US09/015,001 US6060478A (en)	1996-07-24	1998-01-28	Azolo triazines and pyrimidines
US09/015,002 US6191131B1 (en)	1997-07-23	1998-01-28	Azolo triazines and pyrimidines

Publications (1)

Publication Number	Publication Date
ATE301657T1 true ATE301657T1 (de)	2005-08-15

Family

ID=27360164

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT03075887T ATE301657T1 (de)	1998-01-28	1999-01-28	Azolo-pyrimidine
AT99904382T ATE264860T1 (de)	1998-01-28	1999-01-28	Pyrazolotriazine als crf antagonisten

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT99904382T ATE264860T1 (de)	1998-01-28	1999-01-28	Pyrazolotriazine als crf antagonisten

Country Status (19)

Country	Link
EP (2)	EP1049699B1 (de)
JP (1)	JP4228332B2 (de)
KR (1)	KR100574313B1 (de)
CN (2)	CN1137123C (de)
AT (2)	ATE301657T1 (de)
AU (1)	AU748818C (de)
BR (1)	BR9908206A (de)
CA (2)	CA2614603C (de)
DE (2)	DE69926665T2 (de)
DK (2)	DK1344779T3 (de)
ES (2)	ES2247478T3 (de)
IL (1)	IL137019A0 (de)
NZ (2)	NZ524842A (de)
PL (1)	PL200939B1 (de)
PT (2)	PT1049699E (de)
SG (1)	SG111076A1 (de)
SI (2)	SI1344779T1 (de)
TW (1)	TW520372B (de)
WO (1)	WO1999038868A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4331500A (en)	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolotriazines as crf antagonists
US6432989B1 (en)	1999-08-27	2002-08-13	Pfizer Inc	Use of CRF antagonists to treat circadian rhythm disorders
PL354784A1 (en)	1999-09-30	2004-02-23	Neurogen Corporation	Certain alkylene diamine-substituted heterocycles
CA2379585C (en)	1999-09-30	2006-06-20	James W. Darrow	Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
US6525067B1 (en)	1999-11-23	2003-02-25	Pfizer Inc	Substituted heterocyclic derivatives
AU2001263329A1 (en) *	2000-05-18	2001-11-26	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods relating thereto
AU2001275784A1 (en) *	2000-08-02	2002-02-13	Malope Company Limited	Diagnosis and treatment of non-ulcer dyspepsia based on hypothalamic-pituitary-adrenal axis abnormality
NZ528207A (en)	2001-03-13	2006-02-24	Bristol Myers Squibb Pharma Co	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
FR2842809A1 (fr) *	2002-07-26	2004-01-30	Greenpharma Sas	NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US7034023B2 (en) *	2003-04-04	2006-04-25	Pfizer Inc	Pyrrolo[1,2-B]pyridazine compounds and their uses
US7056920B2 (en) *	2003-04-04	2006-06-06	Pfizer Inc	Pyrrolo[1,2-B]pyridazine compounds and their uses
JP2007515474A (ja) *	2003-12-22	2007-06-14	エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド	Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
MY143499A (en) *	2003-12-22	2011-05-31	Sb Pharmco Inc	Crf receptor antagonist and methods relating thereto
EP1722826A2 (de) *	2004-02-13	2006-11-22	SB Pharmco Puerto Rico Inc.	Crf-rezeptor-antagonisten, deren herstellung, deren pharmazeutische zusammensetzung und deren verwendung
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
PE20070855A1 (es) *	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US7851468B2 (en) *	2006-05-15	2010-12-14	Cephalon, Inc.	Substituted pyrazolo[3,4-d]pyrimidines
US10166271B2 (en)	2006-06-21	2019-01-01	The Regents Of The University Of California	Methods for promoting hair growth
US8513276B2 (en)	2006-12-22	2013-08-20	Astex Therapeutics Limited	Imidazo[1,2-a]pyridine compounds for use in treating cancer
HRP20150642T1 (hr)	2006-12-22	2015-08-14	Astex Therapeutics Limited	BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
GB0720041D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New Compounds
GB0720038D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New compounds
GB0810902D0 (en)	2008-06-13	2008-07-23	Astex Therapeutics Ltd	New compounds
GB0906472D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
GB0906470D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
CN104876935B (zh) *	2015-05-18	2017-04-19	南方医科大学	2‑氨基吡咯并[1,2‑f][1,2,4]三嗪类化合物、合成方法及应用
AU2016284638B2 (en) *	2015-06-24	2020-01-23	Curovir Ab	Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
JP7285222B2 (ja) *	2017-08-14	2023-06-01	スプルースバイオサイエンシズインコーポレイテッド	副腎皮質刺激ホルモン放出因子受容体拮抗薬
WO2019036503A1 (en)	2017-08-14	2019-02-21	Spruce Biosciences, Inc.	CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
CN112028891B (zh) *	2019-07-30	2022-07-05	厦门宝太生物科技股份有限公司	腺苷受体拮抗剂
KR20240023691A (ko)	2020-08-12	2024-02-22	스프루스 바이오사이언시스 인코포레이티드	다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW530047B (en) *	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
EP0770080B1 (de) *	1995-05-12	1999-07-14	Neurogen Corporation	Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
AU713673B2 (en) *	1996-02-07	1999-12-09	Neurocrine Biosciences Inc.	Pyrazolopyrimidines as crf receptor antagonists
HU229024B1 (en) *	1996-07-24	2013-07-29	Bristol Myers Squibb Pharma Co	Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
JP3621706B2 (ja) *	1996-08-28	2005-02-16	ファイザー・インク	置換された６，５―ヘテロ―二環式誘導体

1999
- 1999-01-28 AT AT03075887T patent/ATE301657T1/de active
- 1999-01-28 SI SI9930817T patent/SI1344779T1/sl unknown
- 1999-01-28 BR BR9908206-3A patent/BR9908206A/pt not_active Application Discontinuation
- 1999-01-28 DE DE69926665T patent/DE69926665T2/de not_active Expired - Lifetime
- 1999-01-28 PT PT99904382T patent/PT1049699E/pt unknown
- 1999-01-28 EP EP99904382A patent/EP1049699B1/de not_active Expired - Lifetime
- 1999-01-28 JP JP2000529335A patent/JP4228332B2/ja not_active Expired - Fee Related
- 1999-01-28 KR KR1020007008188A patent/KR100574313B1/ko not_active Expired - Fee Related
- 1999-01-28 AT AT99904382T patent/ATE264860T1/de active
- 1999-01-28 PT PT03075887T patent/PT1344779E/pt unknown
- 1999-01-28 NZ NZ524842A patent/NZ524842A/en not_active IP Right Cessation
- 1999-01-28 DE DE69916578T patent/DE69916578T2/de not_active Expired - Lifetime
- 1999-01-28 DK DK03075887T patent/DK1344779T3/da active
- 1999-01-28 WO PCT/US1999/001824 patent/WO1999038868A1/en not_active Ceased
- 1999-01-28 IL IL13701999A patent/IL137019A0/xx unknown
- 1999-01-28 CN CNB998023639A patent/CN1137123C/zh not_active Expired - Fee Related
- 1999-01-28 PL PL342183A patent/PL200939B1/pl unknown
- 1999-01-28 AU AU24787/99A patent/AU748818C/en not_active Ceased
- 1999-01-28 CN CNA2003101225466A patent/CN1542010A/zh active Pending
- 1999-01-28 CA CA2614603A patent/CA2614603C/en not_active Expired - Fee Related
- 1999-01-28 CA CA002314613A patent/CA2314613C/en not_active Expired - Fee Related
- 1999-01-28 EP EP03075887A patent/EP1344779B1/de not_active Expired - Lifetime
- 1999-01-28 ES ES03075887T patent/ES2247478T3/es not_active Expired - Lifetime
- 1999-01-28 NZ NZ505079A patent/NZ505079A/en not_active IP Right Cessation
- 1999-01-28 SI SI9930578T patent/SI1049699T1/xx unknown
- 1999-01-28 SG SG200204556A patent/SG111076A1/en unknown
- 1999-01-28 ES ES99904382T patent/ES2218991T3/es not_active Expired - Lifetime
- 1999-01-28 DK DK99904382T patent/DK1049699T3/da active
- 1999-02-23 TW TW088102636A patent/TW520372B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1137123C (zh)	2004-02-04
ES2218991T3 (es)	2004-11-16
BR9908206A (pt)	2000-12-05
AU748818C (en)	2003-11-20
EP1344779B1 (de)	2005-08-10
WO1999038868A1 (en)	1999-08-05
TW520372B (en)	2003-02-11
CN1289335A (zh)	2001-03-28
KR100574313B1 (ko)	2006-04-27
DE69916578T2 (de)	2005-03-31
DE69916578D1 (de)	2004-05-27
KR20010040426A (ko)	2001-05-15
CA2614603A1 (en)	1999-08-05
DE69926665D1 (de)	2005-09-15
DK1049699T3 (da)	2004-07-05
CA2614603C (en)	2011-08-16
CA2314613A1 (en)	1999-08-05
CN1542010A (zh)	2004-11-03
IL137019A0 (en)	2001-06-14
PL342183A1 (en)	2001-05-21
CA2314613C (en)	2009-12-08
SI1344779T1 (sl)	2006-02-28
AU748818B2 (en)	2002-06-13
EP1344779A1 (de)	2003-09-17
ATE264860T1 (de)	2004-05-15
JP2002501922A (ja)	2002-01-22
NZ505079A (en)	2003-08-29
HK1060348A1 (en)	2004-08-06
SG111076A1 (en)	2005-05-30
PT1049699E (pt)	2004-08-31
DE69926665T2 (de)	2006-06-08
AU2478799A (en)	1999-08-16
EP1049699B1 (de)	2004-04-21
EP1049699A1 (de)	2000-11-08
NZ524842A (en)	2003-10-31
ES2247478T3 (es)	2006-03-01
PL200939B1 (pl)	2009-02-27
PT1344779E (pt)	2005-10-31
JP4228332B2 (ja)	2009-02-25
DK1344779T3 (da)	2005-09-05
SI1049699T1 (en)	2004-10-31

Legal Events

Date

Code

Title

Description

2006-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1344779

Country of ref document: EP

Publication	Publication Date	Title
DE69926665D1 (de)	2005-09-15	Azolo-Pyrimidine
LV12292A (lv)	1999-06-20	Triazinu un pirimidinu azoloatvasinajumi
DE69726724D1 (de)	2004-01-22	Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
BR9814458A (pt)	2001-10-23	Composto, composição farmacêutica e método de tratamento de disfunções afetivas
MY132871A (en)	2007-10-31	Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
LV12262A (lv)	1999-04-20	Ar arilaminu kondenseti piridini un pirimidini
CY1106607T1 (el)	2012-01-25	4-(2-βουτυλαμιονο)-2,7-διμεθυλ-8-(2-μεθυλ-6-μεθοξυπυριδ-3-υλ) πυραζολο-1,5-αι-1,3,5-τριαζινη, τα εναντιομορα και φαρμακευτικως παραδεκτα αλατα αυτης ως συναρμοτες του υποδοχεα του παραγοντος απελευθερωσης κορτικοτροπινης
BR9307646A (pt)	1999-05-25	Pirrolopirimidinas como antagonistas de crf
PT1140929E (pt)	2004-02-27	1h-imidazo¬4,5-d\|piridazin-7-onas 3h-imidazo¬4,5-c\|piridin-4-onas e as tionas correspondentes como ligandos receptores do factor de libertacao de corticotrofina (flc)
ATE198895T1 (de)	2001-02-15	Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
WO2002004453A3 (en)	2002-06-13	PYRROLO[3,4-d]PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
ATE113591T1 (de)	1994-11-15	4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
MY141752A (en)	2010-06-30	Pyrazolotriazines as crf antagonists
MY141976A (en)	2010-08-16	Azolo triazines and pyrimidines
MY141511A (en)	2010-05-14	Azolo triazines and pyrimidines
CA2532925A1 (en)	1998-01-29	Azolo triazines and pyrimidines
Manelis et al.	2000	Neuropsychological model of brain organization of higher psychic functions in children suffering bronchial asthma